Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ACT-129968 in allergic asthma
2009-011975-60Phase 2Completed
- Sponsor
- Actelion Pharmaceuticals Ltd
- Start
- Sep 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of setipiprant in allergic asthma (3 arms), sponsored by Actelion Pharmaceuticals Ltd. Primary endpoint: Change from baseline in FEV1 percentage of predicted normal value. Started Sep 2009; status: completed.
02
Drugs
setipiprant
03
Conditions
allergic asthma
Beyond the preview
Go deeper on 2009-011975-60.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-011975-60.